What amount sold does Immunomic Therapeutics, Inc. report in Form D filings?

The latest linked filings report $104.4M sold across 9 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Immunomic Therapeutics, Inc.'s most recent SEC filing?

Immunomic Therapeutics, Inc.'s most recent Form D filing was on 2025-06-02.

How many investors does Immunomic Therapeutics, Inc. have?

The most recent Form D filing lists 1 investor(s).

What type of securities does Immunomic Therapeutics, Inc. offer?

Immunomic Therapeutics, Inc.'s SEC Form D filings indicate equity offerings.

Immunomic Therapeutics, Inc.

CIK: 0001543256·Biotechnology·ROCKVILLE, MD·Corporation

Reported Sold

$104,391,532

Total Filings

Identified Offerings

Last Filed

Jun 2, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jun 2, 2025Form D — New notice

Reported sold: $6,500,000 · Target: $16,000,000

Rule 506(b)·1 investor

Apr 10, 2024Form D — New notice

Reported sold: $3,000,000 · Target: $20,900,000

Rule 506(b)·1 investor

Jan 14, 2021Form D/A — Amendment

Reported sold: $77,728,230 · Target: $77,728,230

Rule 506(b)·6 investors

Changed: Reported amount sold, Offering target, Reported investors, Sales commissions

Feb 26, 2020Form D — New notice

Reported sold: $10,000,000 · Target: $60,000,000

Rule 506(b)·1 investor

Aug 3, 2018Form D — New notice

Reported sold: $314,500 · Target: $314,500

Rule 506(b)·1 investor

Mar 15, 2017Form D — New notice

Reported sold: $4,629,750 · Target: $10,000,000

Rule 506(b)·47 investors

Oct 15, 2014Form D/A — Amendment

Reported sold: $6,755,052 · Target: $8,800,000

Rule 506(b)·56 investors

Changed: Reported amount sold, Reported investors, Sales commissions

Oct 15, 2014Form D/A — Amendment

Reported sold: $6,755,052 · Target: $8,800,000

Rule 506(b)·56 investors

Apr 24, 2014Form D — New notice

Reported sold: $1,029,000 · Target: $8,800,000

Rule 506(b)·10 investors

Jun 12, 2013Form D/A — Amendment

Reported sold: $1,617,000 · Target: $2,000,000

Rule 506·60 investors

Changed: Reported amount sold, Reported investors

Jun 12, 2013Form D — New notice

Reported sold: $1,117,500 · Target: $1,300,000

Rule 506·30 investors

Jun 12, 2013Form D — New notice

Reported sold: $2,729,500 · Target: $3,000,000

Rule 506·36 investors

Mar 5, 2012Form D — New notice

Reported sold: $1,101,260 · Target: $2,000,000

Rule 506·7 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$3,385,129

Amendment Rate

31%

Latest reported sold across 9 identified offerings

$104,391,532

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

William Barry McDonald

Related Person

Appears on 7 filings

William G Hearl

Related Person

Appears on 7 filings

Ronald Thiboutot

Related Person

Appears on 7 filings

Bernard C Rudnick

Related Person

Appears on 7 filings

James Wishart

Related Person

Appears on 7 filings

C. ERIC WINZER

Related Person

Appears on 5 filings

Winston I Lowe

Related Person

Appears on 4 filings

Bruce Mackler

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jun 2, 2025	New	$16,000,000	$6,500,000	1
Apr 10, 2024	New	$20,900,000	$3,000,000	1
Jan 14, 2021	Amendment	$77,728,230	$77,728,230	6
Feb 26, 2020	New	$60,000,000	$10,000,000	1
Aug 3, 2018	New	$314,500	$314,500	1
Mar 15, 2017	New	$10,000,000	$4,629,750	47
Oct 15, 2014	Amendment	$8,800,000	$6,755,052	56
Oct 15, 2014	Amendment	$8,800,000	$6,755,052	56
Apr 24, 2014	New	$8,800,000	$1,029,000	10
Jun 12, 2013	New	$3,000,000	$2,729,500	36
Jun 12, 2013	New	$1,300,000	$1,117,500	30
Jun 12, 2013	Amendment	$2,000,000	$1,617,000	60
Mar 5, 2012	New	$2,000,000	$1,101,260	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

OS Therapies Inc

Biotechnology

Offering target: $12,282,478

Filed Oct 23, 2026